ESMO 2022 | Treating metastatic breast cancer with metronomic VEX in the METEORA-II trial

Elisabetta Munzone, MD, Istituto Europeo di Oncologia, Milan, Italy, provides an overview of the Phase II METEORA-II trial (NCT02954055), which compared metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) to weekly paclitaxel in patients with ER+/HER2- metastatic breast cancer. 140 patients were enrolled, with time to treatment failure (TTF) as the primary endpoint. Metronomic VEX demonstrated superior TTF comparted to paclitaxel, suggesting that VEX should be a first-line therapy for this subset of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.